Our study revealed that combining a lentivirus targeting METTL1 with abemaciclib is more effective at inhibiting tumour growth than either treatment alone is, suggesting that developing agonists for METTL1 could be a promising therapeutic strategy to increase the efficacy of CDK4/6 inhibitors in treating BC.38 This evidence concerns the gene METTL1 and breast cancer.